MCID: END047
MIFTS: 52

Endophthalmitis

Categories: Eye diseases, Rare diseases

Aliases & Classifications for Endophthalmitis

MalaCards integrated aliases for Endophthalmitis:

Name: Endophthalmitis 12 58 54 43 15 71

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases
Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:4692
MeSH 43 D009877
NCIt 49 C34586
SNOMED-CT 67 1847009 82255004
ICD10 32 H45.1
MESH via Orphanet 44 D009877
ICD10 via Orphanet 33 H44.0 H44.1
UMLS via Orphanet 72 C0014236
Orphanet 58 ORPHA199323
UMLS 71 C0014236

Summaries for Endophthalmitis

Disease Ontology : 12 A globe disease that is characterized by inflammation of the inside of the eye.

MalaCards based summary : Endophthalmitis is related to chronic endophthalmitis and acute endophthalmitis, and has symptoms including redness or discharge of eye An important gene associated with Endophthalmitis is CARD9 (Caspase Recruitment Domain Family Member 9), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Allograft rejection. The drugs Cefazolin and Clindamycin have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and endothelial, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 74 Endophthalmitis is an inflammation of the interior of the eye. It is a possible complication of all... more...

Related Diseases for Endophthalmitis

Diseases in the Endophthalmitis family:

Chronic Endophthalmitis Acute Endophthalmitis

Diseases related to Endophthalmitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 831)
# Related Disease Score Top Affiliating Genes
1 chronic endophthalmitis 34.6 MRAP ASPRV1
2 acute endophthalmitis 34.6 VEGFA PRF1 ASPRV1
3 purulent endophthalmitis 34.5 VEGFA PRF1 ASPRV1
4 sympathetic ophthalmia 31.8 TNF SELE ICAM1
5 hypopyon 31.2 VEGFA MRAP IL6 CRP ASPRV1
6 uveitis 31.2 TNF SAG IL6 ICAM1 CRYAA
7 neuroretinitis 31.1 SAG MRAP CRP
8 panuveitis 30.9 VEGFA TNF SAG MRAP IL6 CRP
9 retinal vein occlusion 30.8 VEGFA TNF IL6
10 keratitis, hereditary 30.8 VEGFA TNF TLR2 IL6 CRYAA
11 haemophilus influenzae 30.7 TNF TLR2
12 conjunctivitis 30.6 TNF PLG IL6 ICAM1
13 cataract 30.6 VEGFA TNF IL6 ICAM1 CRYAA CRP
14 scleritis 30.6 TNF SELE MRAP CRP
15 kuhnt-junius degeneration 30.6 VEGFB VEGFA PLG PGF
16 iridocyclitis 30.6 TNF MRAP IL6 CRP ASPRV1
17 chorioretinitis 30.6 VEGFA TNF SAG MRAP IL6
18 erythema multiforme 30.5 TNF IL6 ICAM1
19 osteomyelitis 30.5 TNF TLR2 IL6
20 central retinal vein occlusion 30.4 VEGFA PLG IL6
21 candidiasis 30.4 TNF TLR2 IL6 DEFB1 CARD9
22 iritis 30.4 TNF MRAP IL6 CRP
23 cellulitis 30.4 TNF LAMA3 IL6 CRP
24 vasculitis 30.4 TNF SELE IL6 ICAM1 CRP
25 branch retinal artery occlusion 30.4 VEGFA PLG CRP
26 diabetic macular edema 30.4 VEGFB VEGFA PGF IL6 ICAM1
27 choroiditis 30.4 VEGFA TNF SAG MRAP
28 septic arthritis 30.3 TLR2 MRAP CRP
29 vitreous detachment 30.3 VEGFB VEGFA PLG LAMA3
30 intermediate uveitis 30.2 TNF MRAP IL6
31 hydrocele 30.2 VEGFA SELE ICAM1
32 neovascular glaucoma 30.2 VEGFB VEGFA PLG PGF
33 posterior uveitis 30.2 TNF SAG MRAP IL6
34 infective endocarditis 30.2 TNF TLR2 IL6 CRP
35 retinal ischemia 30.1 VEGFA TNF CRYAA
36 retinal disease 30.1 SAG HMGB1 CRYAA ALB
37 endocarditis 30.1 TNF TLR2 IL6 CRP ALB
38 microvascular complications of diabetes 5 30.1 VEGFA PLG PGF ICAM1 CRYAA ALB
39 rubeosis iridis 30.1 VEGFA PLG LAMA3
40 central retinal artery occlusion 30.1 VEGFA PLG CRYAA CRP
41 cardiogenic shock 30.0 IL6 CRP
42 herpes zoster 30.0 TNF TLR2 CRP
43 brucellosis 30.0 TNF IL6 CRP
44 spondylitis 30.0 TNF IL6 CRP
45 anterior scleritis 30.0 MRAP CRP
46 ocular melanoma 30.0 VEGFA TNF PLG
47 corneal neovascularization 30.0 VEGFA PLG CRYAA
48 erysipelas 29.9 TNF IL6 CRP
49 pharyngitis 29.9 TNF IL6 CRP
50 severe cutaneous adverse reaction 29.9 TNF PRF1 CRP ALB

Graphical network of the top 20 diseases related to Endophthalmitis:



Diseases related to Endophthalmitis

Symptoms & Phenotypes for Endophthalmitis

UMLS symptoms related to Endophthalmitis:


redness or discharge of eye

MGI Mouse Phenotypes related to Endophthalmitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 ALB CARD9 CRP ICAM1 IL6 LAMA3
2 cardiovascular system MP:0005385 10.23 ALB CRP ICAM1 IL6 PGF PLG
3 immune system MP:0005387 10.18 ALB CARD9 CRP ICAM1 IL6 LAMA3
4 integument MP:0010771 10.06 ASPRV1 ICAM1 IL6 LAMA3 PGF PLG
5 digestive/alimentary MP:0005381 10.03 ALB ICAM1 IL6 LAMA3 PLG TLR2
6 liver/biliary system MP:0005370 9.91 ALB IL6 MRAP PLG PRF1 SELE
7 neoplasm MP:0002006 9.81 ALB ICAM1 IL6 PGF PLG PRF1
8 respiratory system MP:0005388 9.61 IL6 LAMA3 MRAP PGF PLG SELE
9 vision/eye MP:0005391 9.28 ICAM1 IL6 PGF PLG SAG SELE

Drugs & Therapeutics for Endophthalmitis

Drugs for Endophthalmitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefazolin Approved Phase 4 25953-19-9 656510 33255
2
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
3
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
4
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
5
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
6
Polyestradiol phosphate Approved Phase 4 28014-46-2
7
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
8
Vancomycin Approved Phase 4 1404-90-6 441141 14969
9
Bevacizumab Approved, Investigational Phase 4 216974-75-3
10
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
11
Ofloxacin Approved Phase 4 82419-36-1 4583
12
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
13
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
14
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
15
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
16
Ranibizumab Approved Phase 4 347396-82-1 459903
17
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
18
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
19 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
20
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
21
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
22
Bromfenac Approved Phase 4 91714-94-2 60726
23
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
24
Iodine Approved, Investigational Phase 4 7553-56-2 807
25
Povidone Approved Phase 4 9003-39-8
26
Povidone-iodine Approved Phase 4 25655-41-8
27
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
28
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
29 Cephalosporins Phase 4
30 Gentamicins Phase 4
31 Clindamycin palmitate Phase 4
32 Clindamycin phosphate Phase 4
33 Contraceptive Agents Phase 4
34 Norgestimate, ethinyl estradiol drug combination Phase 4
35 Estradiol 17 beta-cypionate Phase 4
36 Contraceptives, Oral, Combined Phase 4
37 Contraceptives, Oral Phase 4
38 Estradiol 3-benzoate Phase 4
39 Renal Agents Phase 4
40 Anti-Infective Agents, Urinary Phase 4
41 Immunologic Factors Phase 4
42 triamcinolone acetonide Phase 4
43 Triamcinolone diacetate Phase 4
44 Immunosuppressive Agents Phase 4
45 Triamcinolone hexacetonide Phase 4
46 Antineoplastic Agents, Immunological Phase 4
47 Topoisomerase Inhibitors Phase 4
48 Endothelial Growth Factors Phase 4
49 Mitogens Phase 4
50 Angiogenesis Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 118)
# Name Status NCT ID Phase Drugs
1 Cefazolin-Lidocaine Solution for Reducing Pain Associated With Subconjunctival Antibiotic Prophylaxis in Vitreo-Retinal Surgery Unknown status NCT02324166 Phase 4 Cefazolin;Lidocaine
2 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
3 Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis Completed NCT00398658 Phase 4 gentamycin and clindamycin
4 Comparative Efficacy of Two Different Regimens of Povidone-iodine 5% Eye Drops Instillation in Reducing Conjunctival Bacterial Flora Completed NCT01739920 Phase 4
5 Prospective, Randomized, Double-blind Comparison of 5 % Against 1.25 % Povidone-iodine Solution as Preoperative Antisepsis for Strabismus Surgery in Young Children Completed NCT00461656 Phase 4 Preoperative conjunctival irrigation with 5% or 1.25% PI
6 Phase 4 Study on Effectiveness of Topical 0.5% Levofloxacin on Reduction of Preoperative Conjunctival Flora in Patients Scheduled for Intraocular Surgery Completed NCT00491049 Phase 4 0.5% levofloxacin eye drops
7 To Compare the Efficacy of Topical Vigamox Eye Drops at Tid 3 Days Prior to Intravitreal Injection Versus Tid 1 Day Prior to Intravitreal Injection Completed NCT00690313 Phase 4 Vigamox
8 A Two Different Chemoprophylaxis Approaches After Phacoemulsification Surgery in One Thousand Patients in Iraq :a Clinical Trial Completed NCT03634852 Phase 4 Moxifloxacin hydrochloride 0.5% eye drops;Dexamethasone 0.1% eye drops;Intracameral Moxifloxacin 0.1%;Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml
9 Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery Completed NCT02819908 Phase 4 Imprimis Dropless;Imprimis Less Drops
10 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
11 Evaluation on Efficacy of Topical Nepafenac as Supplement Therapy in the Treatment of Diabetic Macular Edema Completed NCT02443012 Phase 4 Topical Gutt Nepafenac 0.1%
12 Comparison of Dropless Prophylaxis After Routine Phacoemulsification to Standard Drops Regimen Completed NCT02515045 Phase 4 TriMoxiVanc;Moxifloxacin HCl 0.5%;Ilevro;Prednisolone acetate 1%
13 Evaluation of the Effect of Repeated Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using Optical Coherence Tomography Angiography Completed NCT03246152 Phase 4 Bevacizumab
14 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
15 A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD. Completed NCT01628354 Phase 4 Ranibizumab
16 A Phase IV OpenLabelled Prospective Pilot Study of Intravitreal Macugen (Pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME Study) Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
17 Evaluation and Comparison of Macular and Choroidal Thickness After Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis Recruiting NCT03363295 Phase 4 Moxifloxacin Injection
18 Lessdrops™ Prophylactic Treatment After Routine Phacoemulsification Compared to Standard Drops Regimen Recruiting NCT03578276 Phase 4 Pred-Gati-Brom;Prednisolone acetate 1% ophthalmic suspension;Gatifloxacin Ophthalmic;Bromfenac 0.075% Oph Solution
19 Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. Recruiting NCT03458923 Phase 4 Diclofenac Sodium 0.1 ml containing 500µg;Ranibizumab 0.5 mg Solution for Injection
20 Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study) Not yet recruiting NCT04018482 Phase 4
21 Randomized, Double Blind, Controlled Study With Verteporfin Photodynamic Therapy And Intravitreal Triamcinolone(IVTA) Vs Triple Therapy With Verteporfin Photodynamic Therapy, Intravitreal Triamcinolone And Intravitreal Ranibizumab In Patients With Subfoveal Choroidal Neovascularization(CNV) Secondary To Age-Related Macular Degeneration(AMD) Unknown status NCT00930189 Phase 2, Phase 3 intravitreal injection of ranibizumab;intravitreal injection of triamcinolone
22 Efficacy and Safety of Intravitreal Triamcinolone as Treatment of the Diffuse Diabetic Macular Edema Unknown status NCT00309192 Phase 3 Triamcinolone Acetonide 4 mg intravitreal injection
23 A Randomized, Prospective, Double Masked Clinical Trial of Life 4°C Versus Optisol GS Corneal Storage Media Unknown status NCT01657500 Phase 3
24 Interest of Intravitreal Corticotherapy as the First-line Treatment for Post-operative Endophthalmitis. Completed NCT01768078 Phase 3
25 Endophthalmitis Vitrectomy Study (EVS) Completed NCT00000130 Phase 3 Intravitreal Antibiotics
26 Retaane® in Age-Related Macular Degeneration Completed NCT00569569 Phase 2, Phase 3 juxtascleral depot injection of Retaane
27 Clinical Study for Evaluating the Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration. Completed NCT03668054 Phase 3 Bevacizumab (Lumiere®)
28 Systemic Bevacizumab (Avastin) Therapy for Exudative Neovascular Age-Related Macular Degeneration Completed NCT00531024 Phase 2, Phase 3 Bevacizumab;Sodium Chloride
29 Intravitreal Bevacizumab and Intravitreal Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA) Completed NCT00997191 Phase 3 Intravitreal triamcinolone;Intravitreal bevacizumab
30 The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study Completed NCT00106132 Phase 3 Triamcinolone Acetonide
31 An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy Completed NCT00996437 Phase 2, Phase 3 Ranibizumab;Saline
32 Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery Not yet recruiting NCT03244072 Phase 2, Phase 3 Moxifloxacin;Placebo
33 Intracameral Antibiotic Safety Study Not yet recruiting NCT02590523 Phase 3 Vancomycin;Moxifloxacin;Placebo
34 Use of Intracameral Moxifloxacin for the Prevention of Acute Endophthalmitis Following Cataract Surgery: a Controlled and Randomized Clinical Trial Terminated NCT02770729 Phase 3 Moxifloxacin;No injection of moxifloxacin
35 Prospective Randomized Controlled Trial of Trabectome Versus Trabeculectomy With Mitomycin C in Patients With Open Angle Glaucoma Terminated NCT00901108 Phase 3
36 The Effect of Intravitral Injection of Triamcinolone Combined With Cataract Surgery (Phacoemulsification) on Diabetic Macular Edema and Diabetic Retinopathy Unknown status NCT00849537 Phase 1, Phase 2 Triamcinolone
37 Combined Posterior Sub-Tenon Injection of Triamcinolone Acetonide and Laser Photocoagulation for the Treatment of Clinically Significant Macular Edema Unknown status NCT00229918 Phase 2 triamcinolone acetonide
38 Does Hyperbaric Chamber Improve the Functionality and Symptoms Related to Central Retinal Vein Occlusion (CRVO)? Unknown status NCT02405741 Phase 2
39 Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis Completed NCT02595359 Phase 2 Moxifloxacin
40 Ranibizumab and Reduced Fluence Photodynamic Therapy for Choroidal Neovascularization in Age Related Macular Degeneration Completed NCT00527475 Phase 2 ranibizumab;verteporfin
41 Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration Completed NCT00805233 Phase 2 combination ranibizumab + bromfenac;ranibizumab injection alone
42 Comparative Study of the Efficacy and Safety of Ologen Collagen Implant Versus Cohesive Viscoelastic in Trabeculectomy Performed for Steroid Induced Glaucoma Completed NCT01912638 Phase 1, Phase 2 Provisc
43 An Open Label, Multicenter, Randomized, Uncontrolled Study Assessing the Safety and Efficacy of KH902 in Patients With Choroidal Neovascularization Due to Neovascular Age-related Macular Degeneration(HOPE Study) Completed NCT01242254 Phase 1, Phase 2
44 Phase 2 Ziv-aflibercept in Ocular Disease Short and Long-term Study Recruiting NCT02486484 Phase 2 ziv-aflibercept
45 Phase I/II Comparative Study of a Single Intraoperative Sub-Tenon's Capsule Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System Versus 1% Prednisolone and 0.3% Ciprofloxacin Eyedrops for Cataract Surgery Terminated NCT00431028 Phase 1, Phase 2
46 A Phase I/IIa Study of the Treatment of None-Infectious Anterior, Intermediate, Posterior and Panuveitis, With the Use of Dexamethasone Delivered by a Iontophoresis Device Withdrawn NCT00499551 Phase 1, Phase 2
47 The Safety and Tolerability of Intravitreal Adalimumab in Patients With Refractory Diabetic Macular Retinopathy or Choroidal Neovascularization or Uveitis: A Pilot Study Unknown status NCT00855608 Phase 1 adalimumab
48 Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion Completed NCT00406471 Phase 1 Ranibizumab (Lucentis)
49 Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide Completed NCT02294656 Phase 1 Ranibizumab,;Triamcinolone acetonide
50 Pilot Study of Intravitreal Injection of Triamcinolone Acetonide Formulation for Retinal Vascular Disorders Completed NCT00071227 Phase 1 Triamcinolone Acetonide (TAC-PF)

Search NIH Clinical Center for Endophthalmitis

Cochrane evidence based reviews: endophthalmitis

Genetic Tests for Endophthalmitis

Anatomical Context for Endophthalmitis

MalaCards organs/tissues related to Endophthalmitis:

40
Eye, Liver, Endothelial, Heart, Lung, Retina, Kidney

Publications for Endophthalmitis

Articles related to Endophthalmitis:

(show top 50) (show all 7814)
# Title Authors PMID Year
1
Molecular epidemiology of Staphylococcus aureus and Enterococcus faecalis in endophthalmitis. 54 61
9423880 1998
2
Virulence of enterococci. 54 61
7834601 1994
3
Criteria for intravitreal antibiotics during surgical removal of intraocular foreign bodies. 54 61
1286707 1992
4
Bilateral End-Organ Endophthalmitis in Setting of Serratia marcescens Urosepsis on 18F-FDG PET/CT. 61
31876818 2020
5
Uptake and pharmacokinetics of cefuroxime in rabbits after intravitreal, intracameral, and topical dosing: relevance to human ocular injection of cefuroxime. 61
31144563 2020
6
Diagnostic dilemma: Unilateral panuveitis mimicking endophthalmitis in very severe HLA B27-associated uveitis. 61
31970307 2020
7
Vitreous D-Lactate Levels as a Biomarker in the Diagnosis of Presumed Infectious Culture Negative Endophthalmitis. 61
31466487 2020
8
Pathogenic causes and outcomes of endophthalmitis after vitreoretinal surgeries in Finland from 2009 to 2018. 61
31352683 2020
9
CLINICAL PRESENTATIONS, DIAGNOSIS, AND MANAGEMENT OUTCOMES OF CURVULARIA ENDOPHTHALMITIS AND A REVIEW OF LITERATURE. 61
31972808 2020
10
Indications, Findings, and Outcomes of Pars Plana Vitrectomy after Open Globe Injury. 61
31732470 2020
11
Retinal vascular inflammatory and occlusive changes in infectious and non-infectious uveitis. 61
32016664 2020
12
Long-term survival after cord blood transplantation for acute myeloid leukemia complicated with disseminated fusariosis. 61
31570321 2020
13
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. 61
31474439 2020
14
Cyclophotocoagulation in the Control of Glaucoma in Patients With the Boston Keratoprosthesis Type 1. 61
31335536 2020
15
Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis. 61
32019339 2020
16
The cereus matter of Bacillus endophthalmitis. 61
32032628 2020
17
Decreased painful visual acuity. Corynebacterium macginleyi blebitis-endophthalmitis infection. 61
31915806 2020
18
Methods for achieving low endophthalmitis rates in phacoemulsification cataract surgery. 61
31184434 2020
19
Utility of wound cultures in the management of open globe injuries: a 5-year retrospective review. 61
32009215 2020
20
Endophthalmitis after Cataract Surgery in the United States: A Report from the Intelligent Research in Sight Registry, 2013-2017. 61
31611015 2020
21
Poor penetration of cefcapene into aqueous humor after oral administration of cefcapene pivoxil to patients undergoing cataract surgery. 61
31481306 2020
22
The impact of diabetes mellitus medication on the incidence of endogenous endophthalmitis. 61
31923190 2020
23
Sustained release of levofloxacin from thermosensitive chitosan-based hydrogel for the treatment of postoperative endophthalmitis. 61
30897300 2020
24
Clinical and visual outcome of endophthalmitis patients: a single-center experience. 61
31637487 2020
25
Endophthalmitis after intravitreal injections versus cataract surgery: a 15-year cohort. 61
31414274 2020
26
Intracameral antibiotics for prophylaxis of post-operative endophthalmitis in Australia: Comment. 61
31574583 2020
27
Enterobacter endophthalmitis: Clinical settings, susceptibility profile, and management outcomes across two decades. 61
31856484 2020
28
Commentary: Enterobacter endophthalmitis: Clinical settings, susceptibility profile, and management outcomes across two decades. 61
31856485 2020
29
Recurrence of Infection in Corneal Grafts After Therapeutic Penetrating Keratoplasty for Microbial Keratitis. 61
31259861 2020
30
Colistin resistance in Gram-negative ocular infections: prevalence, clinical outcome and antibiotic susceptibility patterns. 61
31984448 2020
31
Short-Term Clinical Outcomes of a Novel Corneal Prosthetic Device in a Rabbit Model. 61
31990845 2020
32
BLEB-RELATED ENDOPHTHALMITIS AFTER USE OF THE INVITRIA INJECTION GUIDE. 61
28858192 2020
33
Clinical characteristics and visual outcomes of work-related open globe injuries in Japanese patients. 61
31988287 2020
34
The role of pars plana vitrectomy in the management of fungal endogenous endophthalmitis. 61
30474397 2020
35
Safety of 6000 intravitreal dexamethasone implants. 61
31040132 2020
36
Does Endogenous Endophthalmitis Need a More Aggressive Treatment? 61
31951759 2020
37
Infectious conjunctivitis caused by Pseudomonasaeruginosa in infected and extrused scleral buckles. 61
31919063 2020
38
Pars Plana Vitrectomy for Endophthalmitis: Microbiologic Spectrum and Clinical Outcomes. 61
31906757 2020
39
New surgical approach for sutureless scleral fixation. 61
32000520 2020
40
Historical Considerations and Innovations in the Perioperative Use of Mitomycin C for Glaucoma Filtration Surgery and Bleb Revisions. 61
31913225 2020
41
Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases. 61
32001821 2020
42
Uveitis-glaucoma-hyphema syndrome with sclera-fixed posterior-chamber two-haptic intraocular lens in a highly myopic eye: a case report. 61
31924181 2020
43
Outcome of phacoemulsification in 71 cats: A multicenter retrospective study (2006-2017). 61
31328856 2020
44
UTILITY OF INTRAOPERATIVE OPTICAL COHERENCE TOMOGRAPHY IN ACUTE ENDOPHTHALMITIS. 61
28858193 2020
45
Comparative Study of Microbiological Profile and Management Outcomes of Acute Endophthalmitis after Microincision Vitrectomy Surgery versus Intravitreal Injections. 61
31900009 2020
46
Post cataract Pseudomonas stutzeri endophthalmitis: Report of a case and review of literature. 61
31856535 2020
47
Clinical Characteristics and Risk Factors for Complications of Candidaemia in Adults: Focus on Endophthalmitis, Endocarditis, and Osteoarticular Infections. 61
32007642 2020
48
Factors Associated With Positive Microbial Culture in Patients With Endophthalmitis Based on Clinical Presentation and Multimodal Intraocular Sampling. 61
31972748 2020
49
Factors Associated With Positive Microbial Culture in Patients With Endophthalmitis Based on Clinical Presentation and Multimodal Intraocular Sampling. 61
31990738 2020
50
Outcomes and complications of iris-fixated intraocular lenses in cases with inadequate capsular support and complex ophthalmic history. 61
31900437 2020

Variations for Endophthalmitis

Expression for Endophthalmitis

Search GEO for disease gene expression data for Endophthalmitis.

Pathways for Endophthalmitis

Pathways related to Endophthalmitis according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 VEGFB VEGFA TNF TLR2 PGF LAMA3
2
Show member pathways
12.76 VEGFA TNF PRF1 IL6 ICAM1
3
Show member pathways
12.72 TNF TLR2 PLG IL6 ICAM1
4
Show member pathways
12.61 VEGFB TNF TLR2 PGF IL6
5
Show member pathways
12.24 TNF PLG IL6 ICAM1 CRP ALB
6 12.13 TNF TLR2 IL6 CARD9
7 12.08 VEGFA TNF TLR2 IL6
8 11.99 VEGFA TNF SELE ICAM1
9 11.89 VEGFA TNF IL6 ICAM1
10 11.87 TNF SELE IL6 ICAM1
11
Show member pathways
11.83 TNF TLR2 PLG LAMA3 IL6 HMGB1
12 11.82 TNF TLR2 LAMA3 IL6
13 11.77 VEGFA TNF TLR2 IL6 ICAM1
14 11.69 SELE IL6 ICAM1
15 11.52 TNF TLR2 IL6
16
Show member pathways
11.52 VEGFA TNF SELE IL6 ICAM1
17 11.43 TNF IL6 ICAM1
18 11.33 TNF SELE IL6 ICAM1
19 11.25 TNF TLR2 SELE IL6 ICAM1
20 11.1 VEGFB VEGFA TNF SELE IL6 ICAM1
21 11.03 TNF PLG IL6 ICAM1 HMGB1
22 10.95 TNF LAMA3 IL6 CRP
23
Show member pathways
10.86 VEGFB VEGFA PGF
24 10.55 VEGFB VEGFA

GO Terms for Endophthalmitis

Cellular components related to Endophthalmitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.73 VEGFA TNF TLR2 PLG ICAM1 HMGB1
2 extracellular region GO:0005576 9.73 VEGFB VEGFA TNF PRF1 PLG PGF
3 membrane raft GO:0045121 9.62 TNF TLR2 SELE ICAM1
4 platelet alpha granule lumen GO:0031093 9.46 VEGFB VEGFA PLG ALB
5 extracellular space GO:0005615 9.4 VEGFB VEGFA TNF SELE PLG PGF

Biological processes related to Endophthalmitis according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.02 VEGFA TNF TLR2 IL6 CRP
2 inflammatory response GO:0006954 9.93 TNF TLR2 SELE IL6 HMGB1 CRP
3 positive regulation of protein phosphorylation GO:0001934 9.89 VEGFB VEGFA TNF PGF
4 cellular response to lipopolysaccharide GO:0071222 9.88 TNF IL6 ICAM1 HMGB1
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.84 TNF TLR2 IL6 ICAM1
6 platelet degranulation GO:0002576 9.81 VEGFB VEGFA PLG ALB
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 VEGFA TNF IL6
8 positive regulation of endothelial cell proliferation GO:0001938 9.8 VEGFB VEGFA PGF
9 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.78 VEGFB VEGFA PGF
10 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.77 TNF TLR2 HMGB1
11 response to hypoxia GO:0001666 9.77 VEGFB VEGFA TLR2 PGF ICAM1
12 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.74 TNF HMGB1 CARD9
13 positive regulation of tumor necrosis factor production GO:0032760 9.73 TLR2 HMGB1 CARD9
14 positive regulation of cell division GO:0051781 9.72 VEGFB VEGFA PGF
15 positive regulation of interleukin-6 secretion GO:2000778 9.7 TNF TLR2 HMGB1
16 sprouting angiogenesis GO:0002040 9.67 VEGFB VEGFA PGF
17 positive regulation of chemokine production GO:0032722 9.65 TNF TLR2 IL6
18 positive chemotaxis GO:0050918 9.62 VEGFB VEGFA PGF HMGB1
19 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.61 VEGFA PLG
20 vascular endothelial growth factor signaling pathway GO:0038084 9.61 VEGFB VEGFA PGF
21 response to peptidoglycan GO:0032494 9.58 IL6 CARD9
22 induction of positive chemotaxis GO:0050930 9.58 VEGFB VEGFA PGF
23 negative regulation of lipid storage GO:0010888 9.43 TNF IL6 CRP
24 positive regulation of interleukin-6 production GO:0032755 9.35 TNF TLR2 IL6 HMGB1 CARD9
25 positive regulation of mast cell chemotaxis GO:0060754 9.33 VEGFB VEGFA PGF
26 defense response to Gram-positive bacterium GO:0050830 9.1 TNF TLR2 IL6 DEFB1 CRP CARD9

Molecular functions related to Endophthalmitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.81 VEGFA TNF TLR2 PRF1 MRAP DEFB1
2 cytokine activity GO:0005125 9.67 VEGFA TNF IL6 HMGB1
3 growth factor activity GO:0008083 9.62 VEGFB VEGFA PGF IL6
4 vascular endothelial growth factor receptor 1 binding GO:0043183 9.26 VEGFB VEGFA
5 chemoattractant activity GO:0042056 9.26 VEGFB VEGFA PGF HMGB1
6 vascular endothelial growth factor receptor binding GO:0005172 8.8 VEGFB VEGFA PGF

Sources for Endophthalmitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....